49 results on '"Afzali, Anita"'
Search Results
2. Surgery for Crohn’s Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts
3. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial
4. Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
5. Gender barriers are worsening women's access to health care in Afghanistan
6. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
7. 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
8. Su1505: IMPACT OF CONCOMITANT PROTON PUMP INHIBITOR AND ADVANCED THERAPY USE ON HEALTH OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
9. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
10. Su1510: IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS
11. Tu1458: LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
12. Tu1472: RAPIDITY OF OZANIMOD-INDUCED SYMPTOMATIC RESPONSE AND REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PERIOD OF TRUE NORTH
13. Tu1450: EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
14. 969: RECAPTURE OF RESPONSE WITH OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO WITHDREW THERAPY: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
15. IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS
16. Social Media—The Next Glass Ceiling?
17. 611 THE REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF CROHN'S DISEASE
18. Su461 SHORTER DISEASE DURATION IN PATIENTS WITH CROHN'S DISEASE IS ASSOCIATED WITH HIGHER RATES OF REMISSION WITH USTEKINUMAB
19. 460 RAPID INDUCTION EFFECTS OF OZANIMOD ON CLINICAL SYMPTOMS AND INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE INDUCTION PHASE OF TRUE NORTH
20. Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
21. Women’s Health and Ulcerative Colitis
22. Su1507 ESTABLISHING A PEDIATRIC TO ADULT (P2A) TRANSITION FOR PANCREATIC DISEASE: CONNECT-ING INSPPIRE AND PROCEED
23. Sa1854 WOMEN WITH IMMUNE MEDIATED INFLAMMATORY DISEASES WHO USE BIOLOGICS DURING PREGNANCY HAVE A HIGHER RISK FOR POSTPARTUM FLARE
24. Su2069 ELECTIVE VS UNPLANNED SURGICAL INTERVENTIONS FOR BOWEL OBSTRUCTION IN CROHN'S DISEASE: IS THERE A ROLE FOR PREEMPTIVE SURGICAL INTERVENTION?
25. 123 PATIENT AND PHYSICIAN PERSPECTIVES ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: ROLE OF STEROIDS IN THE CONTEXT OF BIOLOGIC THERAPY
26. Mo1892 PREDICTING SUB-OPTIMAL TRANSITIONS IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASES
27. Sa1745 IMPACT OF A PATIENT SUPPORT PROGRAM ON INFLAMMATORY BOWEL DISEASE-RELATED HOSPITALIZATION IN PATIENTS TREATED WITH ADALIMUMAB
28. Su1823 PATIENT AND PHYSICIAN PERSPECTIVES ON THE MANAGEMENT OF INFLAMMATORY BOWEL DISEASE: DISEASE REMISSION AND DURABILITY OF TREATMENT
29. 241 COMBINATION OF SERUM ENDOSCOPIC HEALING INDEX AND THERAPEUTIC DRUG MONITORING ALLOWS FOR NON-INVASIVE TIGHT DISEASE MANAGEMENT IN ADULT PATIENTS WITH CROHN'S DISEASE TREATED WITH ANTI-TUMOR NECROSIS FACTOR THERAPY
30. Tu1905 CANNABIS EFFECT ON INPATIENT DISEASE OUTCOMES IN INFLAMMATORY BOWEL DISEASE AMONG TWO STATES WITH MARIJUANA LEGALIZATION
31. P169 DEFINITION OF REMISSION IN INFLAMMATORY BOWEL DISEASE: ASSESSMENT OF PATIENT AND PHYSICIAN PERSPECTIVES
32. 1042 – Clinical Scores Better Correlate with Complication Rate in Crohn's Disease Patients Undergoing Gastrointestinal Surgery Than Nsqip Or Endoscopic Scores
33. 388. Characteristics and outcomes of prospectively reported pregnancies exposed to certolizumab pegol from a safety database
34. Su1907 - Worsening Severity in Ulcerative Colitis is Associated with Worse Outcomes after Clostridium Difficile Infection
35. Su1903 - Index Severity Score and Early Readmission Predicts Increased Mortality in Crohn's Disease Patients
36. Su1896 - Clostridium Difficile Does not Cause Worse Outcomes in Crohn's Disease
37. Su1888 - Index Severity Score and Early Readmission Predicts Increased Mortality in Ulcerative Colitis Patients
38. 28 CHARACTERISTICS AND OUTCOMES OF PROSPECTIVELY REPORTED PREGNANCIES EXPOSED TO CERTOLIZUMAB PEGOL FROM A SAFETY DATABASE
39. P144 ECONOMIC IMPACT OF SWITCHING FROM ANTI-TNF THERAPY TO ADALIMUMAB, INFIXIMAB OR OTHER ANTI-TNF COMPARED WITH SWITCHING FROM ANTI-TNF THERAPY TO VEDOLIZUMAB
40. P136 CERTOLIZUMAB PEGOL IS EFFECTIVE IN THE MAINTENANCE OF RESPONSE IN MODERATE-SEVERE ULCERATIVE COLITIS: AN OPEN-LABEL MAINTENANCE STUDY
41. P089 PERCEPTIONS REGARDING USE OF ANTI-TUMOR NECROSIS FACTOR TREATMENTS FOR WOMEN OF CHILDBEARING AGE AMONG HEALTHCARE PROFESSIONALS
42. Autoimmune Paradoxical Reactions in Inflammatory Bowel Diseases Longitudinal (April) Cohort: Methodology and Initial Results
43. Outcomes and Economic Impact of Switching from Anti-TNF to Anti-TNF Therapy Compared with Switching from Anti-TNF to Vedolizumab Therapy in Patients with IBD
44. The Incidence of Cardiovascular Events in Patients with Crohn’s Disease Treated with Vedolizumab and Anti-TNF Therapies
45. Sa1814 DNA Aneuploidy in Inflammatory Bowel Disease Patients May Be More Associated With Inflammatory State and Age Over Risk of Developing Colorectal Cancer
46. Su1290 Endoscopic Balloon Dilation for Crohn's Related Strictures: A Single Center Case-Series Experience
47. Mo1760 Assessment of Postoperative Complications in Patients With IBD. A Single Academic Medical Center Experience
48. Tu1309 Assessment of the Efficacy of Oral Methotrexate in Conjunction With Infliximab Therapy for the Treatment of Inflammatory Bowel Disease
49. Survival in Nonalcoholic Steatohepatitis and Cryptogenic Cirrhosis After Liver Transplantation: An Analysis of the Unos Database
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.